(News Bulletin 247) – Turnover is 26.0 million euros for the first three months of 2023 compared to 2.6 million euros for the first quarter of 2022.
For the three-month period ending March 31, 2023, revenue comes mainly from the partial or full recognition of payments received under collaboration and licensing agreements with AstraZeneca, Sanofi and Takeda, the group indicates.
The Company’s cash, cash equivalents and financial assets amounted to €135.0 million as of March 31, 2023.
At the same date, total financial liabilities amounted to €41.1 million. “Cash, cash equivalents and financial assets as of March 31, 2023, do not include the $5 million payment receivable from Takeda,” the company said.
“Our strong cash position was strengthened during the first quarter of 2023 through a licensing agreement with Takeda for antibody conjugates (ADCs) generated from a panel of antibodies developed by Innate, primarily in celiac disease. We also continue to see progress for our molecules from the ANKET® platform with our partner Sanofi presenting preclinical data at major medical congresses supporting the development of ongoing drug candidates,’ said Mondher Mahjoubi, Chairman of the Management Board. from Innate Pharma.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
